Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
MADISON, Wis. - Exact Sciences Corp. (NASDAQ:EXAS), a healthcare diagnostics company with an $8.8 billion market capitalization that InvestingPro analysis suggests is currently undervalued, announced Thursday an expanded partnership with Humana Inc. that will make its Cologuard Plus colorectal cancer screening test available as an in-network service for eligible Humana Medicare Advantage members beginning in August 2025.
The agreement will provide access to the non-invasive screening test to Humana’s approximately 5.8 million Medicare Advantage members. Humana is the fourth largest private insurer in the United States. The deal could further boost Exact Sciences’ impressive 11.6% revenue growth and robust 69.8% gross profit margin.
"The Exact Sciences team is proud to expand access to Cologuard Plus through our collaboration with Humana, making it easier for more people to access this revolutionary, non-invasive colorectal cancer screening test from the comfort of home," said Jake Orville, Executive Vice President and General Manager, Screening at Exact Sciences.
Cologuard Plus, which launched in March 2025, has received FDA approval, Medicare coverage, and inclusion in the U.S. Preventive Services Task Force guidelines. The test is designed for adults aged 45 or older who are at average risk for colorectal cancer.
According to the company, Cologuard Plus features novel biomarkers, improved laboratory processes, and enhanced sample stability compared to the original Cologuard test. Exact Sciences states the newer version is expected to reduce false positives by more than 40% compared to the original test, potentially decreasing unnecessary follow-up colonoscopies. InvestingPro data shows analysts are optimistic about the company’s prospects, with three analysts recently revising their earnings estimates upward and projecting profitability this year.
The original Cologuard test, developed in collaboration with Mayo Clinic, has been used for colorectal cancer screening more than 20 million times since its introduction in 2014. Get deeper insights into Exact Sciences’ growth potential and comprehensive analysis with the Pro Research Report, available exclusively on InvestingPro, along with 5 additional ProTips and extensive financial metrics.
This information is based on a press release statement from Exact Sciences.
In other recent news, Exact Sciences Corp. announced that its Oncodetect molecular residual disease test has received Medicare coverage through the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program. This coverage applies to patients with stage II to IV colorectal cancer and allows for use in both adjuvant and recurrence monitoring settings over a five-year period. Following this announcement, Raymond James upgraded the company’s stock rating to Market Perform, citing the positive Medicare coverage as a key factor. Additionally, Canaccord Genuity reiterated its Buy rating on Exact Sciences, maintaining a $75.00 price target. The firm plans to host a webcast panel to discuss the company’s blood-based test for colorectal cancer screening. Exact Sciences is also set to release its second quarter 2025 financial results on August 6, 2025, with a webcast and conference call scheduled to follow. These developments highlight ongoing progress and interest in the company’s diagnostic offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.